The estimated Net Worth of Matthew Jenusaitis is at least $50.3 Tausend dollars as of 25 August 2021. Matthew Jenusaitis owns over 1,300 units of Hancock Jaffe Laboratories Inc stock worth over $50,260 and over the last 5 years Matthew sold HJLI stock worth over $0.
Sign up
Matthew Jenusaitis HJLI stock SEC Form 4 insiders trading
Matthew has made over 1 trades of the Hancock Jaffe Laboratories Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Matthew bought 1,300 units of HJLI stock worth $10,010 on 25 August 2021.
The largest trade Matthew's ever made was buying 1,300 units of Hancock Jaffe Laboratories Inc stock on 25 August 2021 worth over $10,010. On average, Matthew trades about 433 units every 0 days since 2019. As of 25 August 2021 Matthew still owns at least 4,842 units of Hancock Jaffe Laboratories Inc stock.
You can see the complete history of Matthew Jenusaitis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Matthew Jenusaitis's mailing address?
Matthew's mailing address filed with the SEC is C/O JAFFE LABORATORIES,, 70 DOPPLER, IRVINE, CA, 92618.
Insiders trading at Hancock Jaffe Laboratories Inc
Over the last 6 years, insiders at Hancock Jaffe Laboratories Inc have traded over $1,313,267 worth of Hancock Jaffe Laboratories Inc stock and bought 39,132 units worth $123,953 . The most active insiders traders include Holding, S.A. Biodyne, Robert Andrew Berman und Francis Duhay. On average, Hancock Jaffe Laboratories Inc executives and independent directors trade stock every 100 days with the average trade being worth of $3,344,125. The most recent stock trade was executed by Matthew Jenusaitis on 25 August 2021, trading 1,300 units of HJLI stock currently worth $10,010.
What does Hancock Jaffe Laboratories Inc do?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
What does Hancock Jaffe Laboratories Inc's logo look like?
Complete history of Matthew Jenusaitis stock trades at Hancock Jaffe Laboratories Inc
Hancock Jaffe Laboratories Inc executives and stock owners
Hancock Jaffe Laboratories Inc executives and other stock owners filed with the SEC include:
-
Robert A. Berman,
CEO & Director -
Dr. Marc H. Glickman,
Sr. VP & Chief Medical Officer -
Craig Thomas Glynn,
CFO & Treasurer -
Dr. Benedict Broennimann M.D.,
Chief Medical Officer of Outside of United States -
Warren Hancock,
Co-founder -
Marc H. Glickman,
SVP & Chief Medical Officer -
Marcus W. Robins,
Director -
Sanjay Shrivastava,
Director -
Benedict Broennimann,
Chief Medical Officer, OUS -
Francis Duhay,
Director -
Holding, S.A. Biodyne,
-
Robert Gray,
Director -
Matthew Jenusaitis,
Director -
Craig Glynn,
Chief Financial Officer